193 related articles for article (PubMed ID: 37867433)
1. Efficacy and tolerability of add-on stiripentol in real-world clinical practice: An observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies.
Gil-Nagel A; Aledo-Serrano A; Beltrán-Corbellini Á; Martínez-Vicente L; Jimenez-Huete A; Toledano-Delgado R; Gacía-Morales I; Valls-Carbó A
Epilepsia Open; 2024 Feb; 9(1):164-175. PubMed ID: 37867433
[TBL] [Abstract][Full Text] [Related]
2. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
Buck ML; Goodkin HP
Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540
[No Abstract] [Full Text] [Related]
3. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome.
Yıldız EP; Ozkan MU; Uzunhan TA; Bektaş G; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
J Child Neurol; 2019 Jan; 34(1):33-37. PubMed ID: 30362398
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: A single center prospective observational study.
Rosati A; Boncristiano A; Doccini V; Pugi A; Pisano T; Lenge M; De Masi S; Guerrini R
Epilepsia; 2019 Nov; 60(11):2255-2262. PubMed ID: 31630399
[TBL] [Abstract][Full Text] [Related]
6. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study.
Myers KA; Lightfoot P; Patil SG; Cross JH; Scheffer IE
Dev Med Child Neurol; 2018 Jun; 60(6):574-578. PubMed ID: 29473155
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
[TBL] [Abstract][Full Text] [Related]
8. Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study.
De Liso P; Chemaly N; Laschet J; Barnerias C; Hully M; Leunen D; Desguerre I; Chiron C; Dulac O; Nabbout R
Epilepsy Res; 2016 Sep; 125():42-6. PubMed ID: 27389706
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.
Brigo F; Igwe SC; Bragazzi NL
Cochrane Database Syst Rev; 2017 May; 5(5):CD010483. PubMed ID: 28521067
[TBL] [Abstract][Full Text] [Related]
10. Stiripentol for the treatment of seizures in Dravet syndrome.
Eschbach K; Knupp KG
Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
[TBL] [Abstract][Full Text] [Related]
11. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy.
Brigo F; Storti M
Cochrane Database Syst Rev; 2013 Nov; (11):CD010483. PubMed ID: 24254932
[TBL] [Abstract][Full Text] [Related]
12. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.
Brigo F; Igwe SC
Cochrane Database Syst Rev; 2015 Oct; (10):CD010483. PubMed ID: 26482210
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
[TBL] [Abstract][Full Text] [Related]
14. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
15. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam.
Vasquez A; Wirrell EC; Youssef PE
Expert Rev Neurother; 2023 Apr; 23(4):297-309. PubMed ID: 36975187
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan.
Yamada M; Suzuki K; Matsui D; Inoue Y; Ohtsuka Y
Epilepsy Res; 2021 Feb; 170():106535. PubMed ID: 33388609
[TBL] [Abstract][Full Text] [Related]
17. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
18. Stiripentol open study in Japanese patients with Dravet syndrome.
Inoue Y; Ohtsuka Y; Oguni H; Tohyama J; Baba H; Fukushima K; Ohtani H; Takahashi Y; Ikeda S
Epilepsia; 2009 Nov; 50(11):2362-8. PubMed ID: 19552653
[TBL] [Abstract][Full Text] [Related]
19. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
Chiron C; Helias M; Kaminska A; Laroche C; de Toffol B; Dulac O; Nabbout R; An I
Epilepsia; 2018 Sep; 59(9):1705-1717. PubMed ID: 30132836
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam.
Strzelczyk A; Schubert-Bast S; Reese JP; Rosenow F; Stephani U; Boor R
Epilepsy Behav; 2014 May; 34():86-91. PubMed ID: 24727467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
